Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Edward M, Wolin"'
Autor:
Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, Lucas Huebner, Pamela Kunz, Hagen F Kennecke, Edward M Wolin, Jennifer A Chan, Eileen M O’Reilly, Jeffrey A Meyerhardt, Alan Venook
Publikováno v:
Endocr Relat Cancer
Treatment with the mTOR inhibitor everolimus improves progression-free survival in pancreatic neuroendocrine tumors, but it is not known if the addition of a VEGF pathway inhibitor to an mTOR inhibitor enhances antitumor activity. We performed a rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c8f541bceb5416e86071067671278f
https://doi.org/10.1530/erc-21-0239
https://doi.org/10.1530/erc-21-0239
Publikováno v:
Pancreas. 51:171-176
This study aimed to understand if resection (RS) for nonmetastatic small bowel neuroendocrine tumors (SBNETs) prolongs 5-year overall survival.Patients from National Cancer Data Base with primary histologically confirmed SBNETs from 2007 to 2016 were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83332d0e5421aa86cdc27f29830139e5
https://doi.org/10.1097/mpa.0000000000001982
https://doi.org/10.1097/mpa.0000000000001982
Autor:
Simron Singh, Wieneke Buikhuisen, Jaume Capdevila, Martyn E Caplin, Christian Grohe, Dieter Horsch, Markus Raderer, Diane Reidy-Lagunes, Edward M Wolin, Christelle Pommie, Truong Xuan Mai, Eric Baudin
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fabcc44cf78162b917f792e0d543a340
https://doi.org/10.1530/endoabs.89.c1
https://doi.org/10.1530/endoabs.89.c1
Autor:
Arnaud Demange, Hugo Duarte, Jonathan R. Strosberg, Andrew Eugene Hendifar, James C. Yao, Philippe Ruszniewski, Germo Gericke, Marianne Pavel, Martyn Caplin, Eric P. Krenning, Sakir Mutevelic, Edward M. Wolin, Mariani Maurizio F, Erik Mittra, Pamela L. Kunz, Enrique Grande, Ettore Seregni, Lisa Bodei, Amy Bartalotta, Eric Van Cutsem
Publikováno v:
The Lancet Oncology, 22(12), 1752-1763. Lancet Publishing Group
Summary Background The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0058dd366f1b523fe4859adad415c3
https://doi.org/10.1016/s1470-2045(21)00572-6
https://doi.org/10.1016/s1470-2045(21)00572-6
Autor:
Eric P. Krenning, Philippe Ruszniewski, David L. Bushnell, Andrew Eugene Hendifar, Oscar Leeuwenkamp, Paola Santoro, Beth R Chasen, Edward M. Wolin, Per Broberg, Matthew H. Kulke, Ghassan El-Haddad, Kjell Öberg, Martyn Caplin, Jonathan R. Strosberg, Richard P. Baum, Rajaventhan Srirajaskanthan
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 62, iss 12
Journal of Nuclear Medicine, 62(12), 1712-1718. Society of Nuclear Medicine and Molecular Imaging
Journal of Nuclear Medicine, 62(12), 1712-1718. Society of Nuclear Medicine and Molecular Imaging
We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome. Methods: All patients enrolled in the international randomized phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3c2d6cd0409f21dbd06f05d21eaff1
https://doi.org/10.2967/jnumed.120.258897
https://doi.org/10.2967/jnumed.120.258897
Autor:
Monica Naparst, Naomi Alpert, Michelle K. Kim, Kelly E Diaz, Emanuela Taioli, Elizabeth Kessel, Eugene Ahn, Edward M. Wolin
Publikováno v:
Pancreas. 50:29-36
Objectives The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Methods Using the Surveillance, Epidemiology, and End Results Registry, we i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2005eaf44105d974393a8843f53ecc25
https://doi.org/10.1097/mpa.0000000000001707
https://doi.org/10.1097/mpa.0000000000001707
Autor:
Eva L Alba, Emily A Japp, Gustavo Fernandez-Ranvier, Ketan Badani, Eric Wilck, Munir Ghesani, Andrea Wolf, Edward M Wolin, Virginia Corbett, David Steinmetz, Maria Skamagas, Alice C Levine
Publikováno v:
Journal of the Endocrine Society. 6
Neoplasms that secrete ectopic adrenocorticotropin (ACTH) may cause severe, life-threatening hypercortisolism. These tumors are often difficult to localize and treat, requiring a comprehensive and systematic management plan orchestrated by a multidis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21e6c60df0938fbb5b26f3fc7e29e929
https://doi.org/10.1210/jendso/bvac073
https://doi.org/10.1210/jendso/bvac073
Autor:
Philippe Ruszniewski, Edward M. Wolin, Jarosław B. Ćwikła, Martyn Caplin, Clarinet Investigators, Eva Sedlackova, Marianne Pavel, Alexandria T. Phan, Xuan-Mai Truong Thanh
Publikováno v:
Endocrine
Purpose In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06628a1362074ce9be44a7136f6295d9
https://doi.org/10.1007/s12020-020-02475-2
https://doi.org/10.1007/s12020-020-02475-2
Autor:
Edward M. Wolin, Guido Rindi, Jaume Capdevila, Eva Sedlackova, Guillaume Cadiot, Alexandria T Phan, Philippe Ruszniewski, Jarosław B. Ćwikła, Tal Grenader, Markus Raderer, Xuan-Mai Truong Thanh, Martyn Caplin, Marianne Pavel, Lucy Wall
Publikováno v:
Anti-Cancer Drugs
Grenader, T, Pavel, M E, Ruszniewski, P B, Ćwikła, J, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Thanh, X M T, Caplin, M E & CLARINET Study Group 2020, ' Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors ', Anti-Cancer Drugs, vol. 31, no. 3, pp. 216-222 . https://doi.org/10.1097/CAD.0000000000000909
Scientia
Grenader, T, Pavel, M E, Ruszniewski, P B, Ćwikła, J, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Thanh, X M T, Caplin, M E & CLARINET Study Group 2020, ' Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors ', Anti-Cancer Drugs, vol. 31, no. 3, pp. 216-222 . https://doi.org/10.1097/CAD.0000000000000909
Scientia
Supervivència lliure de progressió; Tumors neuroendocrins Supervivencia libre de progresión; Tumores neuroendocrinos Progression-free survival; Neuroendocrine tumors Accessible prognostic tools are needed to individualize treatment of neuroendocri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545639e3db3f5eae49b6f588edea03a5
https://doi.org/10.1097/cad.0000000000000909
https://doi.org/10.1097/cad.0000000000000909
Publikováno v:
Journal of the American College of Surgeons. 233:e177-e178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b06f33f5632394613120f3fe43240935
https://doi.org/10.1016/j.jamcollsurg.2021.08.480
https://doi.org/10.1016/j.jamcollsurg.2021.08.480